Literature DB >> 1996564

Immunotactoid glomerulopathy.

S M Korbet1, M M Schwartz, E J Lewis.   

Abstract

During the past 10 years, immunotactoid glomerulopathy has become recognized with increasing frequency. The lesion is characterized histologically by highly organized ultrastructural deposits that appear to be composed of immunoglobulin and complement and are negative for amyloid by Congo red stain. Clinically and/or serologically, patients have no evidence of cryoglobulinemia, amyloidosis, systemic lupus erythematosus, or a paraproteinemia, disorders associated with glomerular deposits, which also have a highly organized tactoidal or fibrillar characteristic. Immunotactoid glomerulopathy does not appear to be a multisystemic disease process and thus may represent a primary glomerulopathy. Patients with immunotactoid glomerulopathy present with proteinuria (nephrotic range in more than 60%) and over half of the patients have hypertension, hematuria, and renal insufficiency. Progression to end stage renal disease has occurred in more than 40% of patients reported to date. The experience in treating this disorder using prednisone and/or immunosuppression is limited and has not been impressive. Four patients have successfully undergone renal transplantation, but proteinuria recurred in two and was associated with the recurrence of immunotactoid glomerulopathy in the renal allograft. Although we have gained insight into the clinical course and histopathology of this disorder over the past few years, we still know little about its pathogenesis, an area for further research.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1996564     DOI: 10.1016/s0272-6386(12)80469-0

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  8 in total

1.  Non-Hodgkin's lymphoma associated membranoproliferative glomerulonephritis: rare case of long term remission with chemotherapy: a case report.

Authors:  Hala Alshayeb; Barry M Wall
Journal:  Cases J       Date:  2009-09-15

2.  Fibrillary glomerulonephritis associated with monoclonal gammopathy of undetermined significance showing lambda-type Bence Jones protein.

Authors:  Tomoaki Nagao; Takafumi Okura; Ken-Ichi Miyoshi; Sanae Watanabe; Seiko Manabe; Mie Kurata; Jun Irita; Tomikazu Fukuoka; Jitsuo Higaki
Journal:  Clin Exp Nephrol       Date:  2005-09       Impact factor: 2.801

3.  Recurrence of fibrillary glomerulonephritis in a renal transplant recipient.

Authors:  Ahmed Mitwalli; Iqbal Shah; Durdana Hammad; Hala Kafoury
Journal:  Int Urol Nephrol       Date:  2012-07-24       Impact factor: 2.370

4.  Polyclonal Immunotactoid Glomerulopathy Associated with Monoclonal Gammopathy of IgM Type and Underlying Plasmacellular Disease: Successful Treatment with Rituximab Alone.

Authors:  Wolfgang Neukirchen; Anne Oesterling; Dirk Oliver Wennmann; Barbara Heitplatz; Peter Ritter; Hartmut Merz; Veit Busch
Journal:  Case Rep Nephrol Dial       Date:  2022-04-25

5.  The gene for human fibronectin glomerulopathy maps to 1q32, in the region of the regulation of complement activation gene cluster.

Authors:  M Vollmer; M Jung; F Rüschendorf; R Ruf; T Wienker; A Reis; R Krapf; F Hildebrandt
Journal:  Am J Hum Genet       Date:  1998-12       Impact factor: 11.025

6.  Immunotactoid-like endoneurial deposits in a patient with monoclonal gammopathy of undetermined significance and neuropathy.

Authors:  D F Moorhouse; R I Fox; H C Powell
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

7.  Ultrastructural immunohistochemical localization of polyclonal IgG, C3, and amyloid P component on the congo red-negative amyloid-like fibrils of fibrillary glomerulopathy.

Authors:  G C Yang; R Nieto; I Stachura; G R Gallo
Journal:  Am J Pathol       Date:  1992-08       Impact factor: 4.307

8.  Fibrilo-Tactoid Glomerulonephritis: A Possible Novel Morphological Variant.

Authors:  Amaresh Vanga; Sandeep Magoon; Jolanta Kowalewska; Saad Mussarat
Journal:  Case Rep Nephrol Dial       Date:  2020-11-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.